# REBEAT Resynchronisation and Beta-Blocker European Trial

> **NCT00305526** · PHASE4 · TERMINATED · sponsor: **Guidant Corporation** · enrollment: 354 (estimated)

## Conditions studied

- Heart Failure

## Interventions

- **DEVICE:** Contak Renewal (CRT-D)

## Key facts

- **NCT ID:** NCT00305526
- **Lead sponsor:** Guidant Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-04
- **Primary completion:** —
- **Final completion:** 2007-07
- **Target enrollment:** 354 (ESTIMATED)
- **Why stopped:** lack of enrolment
- **Last updated:** 2007-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00305526

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00305526, "REBEAT Resynchronisation and Beta-Blocker European Trial". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00305526. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*